It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
NIR-II fluorophores have shown great promise for biomedical applications with superior in vivo optical properties. To date, few small-molecule NIR-II fluorophores have been discovered with donor-acceptor-donor (D-A-D) or symmetrical structures, and upconversion-mitochondria-targeted NIR-II dyes have not been reported. Herein, we report development of D-A type thiopyrylium-based NIR-II fluorophores with frequency upconversion luminescence (FUCL) at ~580 nm upon excitation at ~850 nm. H4-PEG-PT can not only quickly and effectively image mitochondria in live or fixed osteosarcoma cells with subcellular resolution at 1 nM, but also efficiently convert optical energy into heat, achieving mitochondria-targeted photothermal cancer therapy without ROS effects. H4-PEG-PT has been further evaluated in vivo and exhibited strong tumor uptake, specific NIR-II signals with high spatial and temporal resolution, and remarkable NIR-II image-guided photothermal therapy. This report presents the first D-A type thiopyrylium NIR-II theranostics for synchronous upconversion-mitochondria-targeted cell imaging, in vivo NIR-II osteosarcoma imaging and excellent photothermal efficiency.
Currently available mitochondria-targeted fluorescent dyes emit only one color in the visible or NIR-I and their applications are limited. Here, the authors develop upconversion mitochondria-targeted NIR-II fluorophores for synchronous upconversion-mitochondria-targeted cell imaging, in vivo NIR-II osteosarcoma imaging and photothermal efficiency
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Wuhan University School of Pharmaceutical Sciences, State Key Laboratory of Virology, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE), Hubei Provincial Key Laboratory of Developmentally Originated Disease, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153); Tibet University, College of Science, Innovation Center for Traditional Tibetan Medicine Modernization and Quality Control, Lhasa, China (GRID:grid.440680.e) (ISNI:0000 0004 1808 3254)
2 Wuhan University School of Pharmaceutical Sciences, State Key Laboratory of Virology, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE), Hubei Provincial Key Laboratory of Developmentally Originated Disease, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153); Shenzhen Institute of Wuhan University, Shenzhen, China (GRID:grid.49470.3e)
3 Wuhan University School of Pharmaceutical Sciences, State Key Laboratory of Virology, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE), Hubei Provincial Key Laboratory of Developmentally Originated Disease, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153)
4 Nanjing University of Posts and Telecommunications, Key Laboratory for Organic Electronics and Information Displays & Institute of Advanced Materials, Nanjing, China (GRID:grid.453246.2) (ISNI:0000 0004 0369 3615)
5 Chengdu University of Traditional Chinese Medicine, Wenjiang, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu, China (GRID:grid.411304.3) (ISNI:0000 0001 0376 205X)
6 University of Aberdeen, Department of Chemistry, Aberdeen, UK (GRID:grid.7107.1) (ISNI:0000 0004 1936 7291)